Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Reata Pharmaceuticals advances SKYCLARYS, faces impurity challenges and growth opportunities

Reata Pharmaceuticals is making significant progress with FDA approvals and commercialization plans for SKYCLARYS. The company is strategically managing resources and focusing on key programs for long-term sustainability. Challenges with impurity issues and discontinuation of bardoxolone program are being addressed while opportunities for label expansion and new asset exploration are being pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. The news flow was light, the trading pattern sideways and volume virtually nonexistent.

The Stock That Tripled in a Day

Amylyx Pharmaceuticals

Apellis Pharma

Ascendis Pharma

Axsome Therapeutics

Cogint

CTI BioPharma

IVERIC bio Inc

Mirati Therapeutics

Seagen

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

These Are the Top 10 Holdings of David Kim

Reata Pharmaceuticals, Inc. recently enjoyed a robust rally due to the FDA approval of its lead drug, omaveloxolone (Oma) for Friedreich's ataxia. The label for omaveloxolone is clean without a boxed warning or any other contraindications.

Reata Pharmaceuticals: The Silver Bullet For Friedreich's Ataxia

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that management will participate in the Barclays Global Healthcare Conference held next week, March 14-16, in Miami, Florida.

Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference

A major regulatory approval lit a fire underneath Reata's shares this week.

Why Reata Pharmaceuticals Stock Skyrocketed This Week

Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product

Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug

The shares of Reata Pharmaceuticals Inc  (NASDAQ:RETA) are up 178.5% at $86.81 this afternoon, after U.S. Food and Drug Administration (FDA) approved the drugmaker's Skyclarys treatment for Friedreich's ataxia, a rare genetic disorder.

Pharma Stock Surges After FDA Approves Treatment

Biopharma company Reata Pharmaceuticals Inc (NASDAQ:RETA) was in the spotlight on Wednesday after a key approval from the US Food and Drug Administration (FDA) sent its stock soaring. The company announced that the FDA had approved omaveloxolone (brand name SKYCLARYS) for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Reata Pharmaceuticals wins key FDA approval for rare disease treatment Friedreich's ataxia, sending shares soaring

Sarepta Therapeutics

Markets are trying to rise, and these companies are helping out.

Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks

Shares of Reata Pharmaceuticals Inc. RETA soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys, a treatment for Friedreich's ataxia, a rare disease that affects an estimated 6,000 people in the U.S. Reata's stock is down 17.9% so far this year, while the broader S&P 500 SPX has gained 3.7%.

Reata's stock jumps 175% in premarket trading after FDA approval

Reata Pharmaceuticals (NASDAQ: RETA ) stock is rocketing higher on Wednesday following approval from the FDA for one of its drugs. The FDA approval covers the use of the company's SKYCLARYS as a treatment for patients suffering from Friedreich's ataxia.

Why Is Reata Pharmaceuticals (RETA) Stock Up 175% Today?

Novavax

Here are U.S. stocks in focus ahead of Wednesday's trading session:

Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts' over future operations

The FDA approves the pharmaceutical company's treatment for Friedreich's ataxia, which Citi analysts expect to generate peak U.S. revenue of around $1.2 billion.

Reata Soars on Approval for Rare Disorder Drug. Its Pipeline Impresses Analysts.

Reata Pharmaceuticals won FDA approval for its neurological disease treatment late Tuesday, shortly after RETA stock was halted. The post Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval appeared first on Investor's Business Daily.

Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval

The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.'s treatment for Friedreich's ataxia, a rare inherited disease that causes damage to the nervous system.

FDA approves Reata's rare nervous-system drug amid questions about changing regulatory environment for neuroscience treatments

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that the U.S. Food and Drug Administration (“FDA”) has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich's Ataxia

The FDA will decide whether to approve a neurological disease drug from Reata Pharmaceuticals this week, but RETA stock plummeted Monday. The post Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit appeared first on Investor's Business Daily.

Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit

Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?

Travere Therapeutics

These two growth stocks might deliver enormous gains for shareholders this month.

The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February

Bardoxolone's Complete Response Letter caused the stock to lose much of its share price last year. The other lead medicine (omaveloxolone) is going to the FDA for Friedrich's Ataxia approval this February.

Reata Pharmaceuticals: Binary Catalyst Unlocking

Reata Pharmaceuticals has an FDA decision (PDUFA) date of February 28 for omaveloxolone. Bardoxolone is in three Phase 3 trials for different types of polycystic kidney disease.

Reata Pharmaceuticals: Buy While Preparing For First Commercial Launch

PLANO, Texas--( BUSINESS WIRE )--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology & Neurology Conference on November 14 – 15, 2022 in New York, NY, and will participate in the Stifel 2022 Healthcare Conference on November 15 – 16, 2022 in New York, NY.

Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference

Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.

Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates

Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Warren Huff - Chief Executive Officer Manmeet Soni - President Colin Meyer - Chief Innovation Officer Seemi Khan - Chief Medical Officer Dawn Bir - Chief Commercial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Kumar - Goldman Sachs Yatin Suneja - Guggenheim Charles Duncan - Cantor Fitzgerald Carter Gould - Barclays Annabel Samimy - Stifel Maurice Raycroft - Jefferies Operator Thank you for standing by, and welcome to the Reata Pharmaceuticals Third Quarter 2022 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call in the Investor section of Reata's website at reatapharma.com.

Reata Pharmaceuticals, Inc. (RETA) Q3 2022 Earnings Call Transcript

Investors are cheering the company's third-quarter update.

News for Reata Pharmaceuticals Stock (RETA)